Petra Heffeter

List of Publications by Year
in descending order

152 papers	6,905 citations	57758 44 h-index	71685 76 g-index
157 all docs	157 docs citations	157 times ranked	8939 citing authors

#	Article	IF	Citations
1	The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation. Pharmaceutics, 2022, 14, 238.	4.5	14
2	A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance. Communications Chemistry, 2022, 5, .	4.5	31
3	Albumin-targeting of an oxaliplatin-releasing platinum(<scp>iv</scp>) prodrug results in pronounced anticancer activity due to endocytotic drug uptake in vivo. Chemical Science, 2021, 12, 12587-12599.	7.4	24
4	The FAM3C locus that encodes interleukin-like EMT inducer (ILEI) is frequently co-amplified in MET-amplified cancers and contributes to invasiveness. Journal of Experimental and Clinical Cancer Research, 2021, 40, 69.	8.6	12
5	Interfering with Metabolic Profile of Tripleâ€Negative Breast Cancers Using Rationally Designed Metformin Prodrugs. Angewandte Chemie, 2021, 133, 13517-13525.	2.0	3
6	Interfering with Metabolic Profile of Tripleâ€Negative Breast Cancers Using Rationally Designed Metformin Prodrugs. Angewandte Chemie - International Edition, 2021, 60, 13405-13413.	13.8	38
7	Structureâ€“Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands. Journal of Medicinal Chemistry, 2021, 64, 12132-12151.	6.4	34
8	Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance. Drug Resistance Updates, 2021, 58, 100778.	14.4	45
9	CD47-targeted cancer immunogene therapy: Secreted SIRPÎ±-Fc fusion protein eradicates tumors by macrophage and NK cell activation. Molecular Therapy - Oncolytics, 2021, 23, 192-204.	4.4	12
10	Liposomal formulations of anticancer copper(<scp>ii</scp>) thiosemicarbazone complexes. Dalton Transactions, 2021, 50, 16053-16066.	3.3	5
11	Discrimination between 34 of 36 Possible Combinations of Three C>T SNP Genotypes in the MGMT Promoter by High Resolution Melting Analysis Coupled with Pyrosequencing Using A Single Primer Set. International Journal of Molecular Sciences, 2021, 22, 12527.	4.1	2
12	Landomycins as glutathione-depleting agents and natural fluorescent probes for cellular Michael adduct-dependent quinone metabolism. Communications Chemistry, 2021, 4, .	4.5	9
13	The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivoâ€”A Comparison of O,O â€, S,O â€, and N , Nâ€•Chelate Effects. Chemistry - A European Journal, 2020, 26, 2211-2221.	3.3	8
14	Methylated Xanthones from the Rootlets of Metaxya rostrata Display Cytotoxic Activity in Colorectal Cancer Cells. Molecules, 2020, 25, 4449.	3.8	0
15	Effects of pharmacological calcimimetics on colorectal cancer cells over-expressing the human calcium-sensing receptor. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118836.	4.1	12
16	Improving the Stability of EGFR Inhibitor Cobalt(III) Prodrugs. Inorganic Chemistry, 2020, 59, 17794-17810.	4.0	11
17	Complex formation and cytotoxicity of Triapine derivatives: a comparative solution study on the effect of the chalcogen atom and NH-methylation. Dalton Transactions, 2020, 49, 16887-16902.	3.3	22
18	Cancer Cell Resistance Against the Clinically Investigated Thiosemicarbazone COTI-2 Is Based on Formation of Intracellular Copper Complex Glutathione Adducts and ABCC1-Mediated Efflux. Journal of Medicinal Chemistry, 2020, 63, 13719-13732.	6.4	33

#	Article	IF	Citations
19	Destabilization of FoxM1 and Inhibition of Topoisomerase I Contribute to Cytotoxicity of Prenylated Xanthones Isolated from Metaxya rostrata. Planta Medica, 2020, 86, 1073-1079.	1.3	4
20	High Copper Complex Stability and Slow Reduction Kinetics as Key Parameters for Improved Activity, Paraptosis Induction, and Impact on Drug-Resistant Cells of Anticancer Thiosemicarbazones. Antioxidants and Redox Signaling, 2020, 33, 395-414.	5.4	28
21	Reactive Oxygen Species (ROS)-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib. Molecules, 2020, 25, 1149.	3.8	6
22	Development and biological investigations of hypoxia-sensitive prodrugs of the tyrosine kinase inhibitor crizotinib. Bioorganic Chemistry, 2020, 99, 103778.	4.1	11
23	Lipid dropletâ€mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib. International Journal of Cancer, 2020, 147, 1680-1693.	5.1	16
24	A-ring and E-ring modifications of the cytotoxic alkaloid Luotonin A: Synthesis, computational and biological studies. Bioorganic and Medicinal Chemistry, 2020, 28, 115443.	3.0	3
25	Identifying new topoisomerase II poison scaffolds by combining publicly available toxicity data and 2D/3D-based virtual screening. Journal of Cheminformatics, 2019, 11, 67.	6.1	5
26	Zweifel an einem Dogma: Hydrolyse Ãquatorialer Liganden von Pt^{IV}â€Komplexen unter physiologischen Bedingungen. Angewandte Chemie, 2019, 131, 7542-7547.	2.0	5
27	A Dogma in Doubt: Hydrolysis of Equatorial Ligands of Pt^{IV} Complexes under Physiological Conditions. Angewandte Chemie - International Edition, 2019, 58, 7464-7469.	13.8	46
28	Position-Selective Synthesis and Biological Evaluation of Four Isomeric A-Ring Amino Derivatives of the Alkaloid Luotonin A. Molecules, 2019, 24, 716.	3.8	14
29	Synthesis and Cytotoxicity of Water-Soluble Dual- and Triple-Action Satraplatin Derivatives: Replacement of Equatorial Chlorides of Satraplatin by Acetates. Inorganic Chemistry, 2019, 58, 16676-16688.	4.0	13
30	Synthesis, Characterization and inâ€…vitro Studies of a Cathepsin Bâ€Cleavable Prodrug of the VEGFR Inhibitor Sunitinib. Chemistry and Biodiversity, 2019, 16, e1800520.	2.1	9
31	Synthesis and biological evaluation of biotin-conjugated anticancer thiosemicarbazones and their iron(III) and copper(II) complexes. Journal of Inorganic Biochemistry, 2019, 190, 85-97.	3.5	32
32	Metal Drugs and the Anticancer Immune Response. Chemical Reviews, 2019, 119, 1519-1624.	47.7	237
33	Anticancer Thiosemicarbazones: Chemical Properties, Interaction with Iron Metabolism, and Resistance Development. Antioxidants and Redox Signaling, 2019, 30, 1062-1082.	5.4	137
34	Bioimaging of isosteric osmium and ruthenium anticancer agents by LA-ICP-MS. Metallomics, 2018, 10, 388-396.	2.4	29
35	Comparison of metabolic pathways of different Î±-N-heterocyclic thiosemicarbazones. Analytical and Bioanalytical Chemistry, 2018, 410, 2343-2361.	3.7	12
36	Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis. OncoImmunology, 2018, 7, e1424676.	4.6	35

#	Article	IF	Citations
37	Quantum Dot Based Luminescent Nanoprobes for Sigma-2 Receptor Imaging. Molecular Pharmaceutics, 2018, 15, 458-471.	4.6	13
38	Long-term exposure of immortalized keratinocytes to arsenic induces EMT, impairs differentiation in organotypic skin models and mimics aspects of human skin derangements. Archives of Toxicology, 2018, 92, 181-194.	4.2	26
39	Lysosomal Sequestration Impairs the Activity of the Preclinical FGFR Inhibitor PD173074. Cells, 2018, 7, 259.	4.1	8
40	The thiosemicarbazone Me2NNMe2 induces paraptosis by disrupting the ER thiol redox homeostasis based on protein disulfide isomerase inhibition. Cell Death and Disease, 2018, 9, 1052.	6.3	38
41	Serum-binding properties of isosteric ruthenium and osmium anticancer agents elucidated by SECâ€“ICPâ€“MS. Monatshefte FÃ¼r Chemie, 2018, 149, 1719-1726.	1.8	22
42	Nanoformulations of anticancer FGFR inhibitors with improved therapeutic index. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 2632-2643.	3.3	22
43	Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance. British Journal of Cancer, 2017, 116, 489-500.	6.4	14
44	Electronic State of Sodium trans-[Tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) in Tumor, Liver and Kidney Tissue of a SW480-bearing Mouse. Scientific Reports, 2017, 7, 40966.	3.3	25
45	{Ru(CO)_x}-Core complexes with benzimidazole ligands: synthesis, X-ray structure and evaluation of anticancer activity in vivo. Dalton Transactions, 2017, 46, 3025-3040.	3.3	27
46	Comparative studies of oxaliplatin-based platinum(<scp>iv</scp>) complexes in different in vitro and in vivo tumor models. Metallomics, 2017, 9, 309-322.	2.4	60
47	Rapid generation of hydrogen peroxide contributes to the complex cell death induction by the angucycline antibiotic landomycin E. Free Radical Biology and Medicine, 2017, 106, 134-147.	2.9	27
48	Distinct activity of the bone-targeted gallium compound KP46 against osteosarcoma cells - synergism with autophagy inhibition. Journal of Experimental and Clinical Cancer Research, 2017, 36, 52.	8.6	28
49	SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers. Molecular Cancer, 2017, 16, 1.	19.2	196
50	EGFR-targeting peptide-coupled platinum(IV) complexes. Journal of Biological Inorganic Chemistry, 2017, 22, 591-603.	2.6	23
51	Post-digestion stabilization of osmium enables quantification by ICP-MS in cell culture and tissue. Analyst, The, 2017, 142, 2327-2332.	3.5	17
52	An Organoruthenium Anticancer Agent Shows Unexpected Target Selectivity For Plectin. Angewandte Chemie - International Edition, 2017, 56, 8267-8271.	13.8	97
53	Irinotecan Upregulates Fibroblast Growth Factor Receptor 3 Expression in Colorectal Cancer Cells, Which Mitigates Irinotecan-Induced Apoptosis. Translational Oncology, 2017, 10, 332-339.	3.7	18
54	Sigma-2 receptor and progesterone receptor membrane component 1 (PGRMC1) are two different proteins: Proofs by fluorescent labeling and binding of sigma-2 receptor ligands to PGRMC1. Pharmacological Research, 2017, 117, 67-74.	7.1	36

#	Article	IF	Citations
55	An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo. Chemical Science, 2017, 8, 2241-2250.	7.4	114
56	Synthesis and in vivo anticancer evaluation of poly(organo)phosphazene-based metallodrug conjugates. Dalton Transactions, 2017, 46, 12114-12124.	3.3	32
57	Sensitivity towards the GRP78 inhibitor KP1339/IT-139 is characterized by apoptosis induction via caspase 8 upon disruption of ER homeostasis. Cancer Letters, 2017, 404, 79-88.	7.2	44
58	InnenrÃ¼cktitelbild: Ein Organoruthenium‐Tumortherapeutikum mit unerwartet hoher SelektivitÃt fÃ¼r Plectin (Angew. Chem. 28/2017). Angewandte Chemie, 2017, 129, 8415-8415.	2.0	0
59	Ein Organoruthenium‐Tumortherapeutikum mit unerwartet hoher SelektivitÃt fÃ¼r Plectin. Angewandte Chemie, 2017, 129, 8379-8383.	2.0	14
60	Multifunctional Î±_vÎ²₆ Integrin-Specific Peptide–Pt(IV) Conjugates for Cancer Cell Targeting. Bioconjugate Chemistry, 2017, 28, 2429-2439.	3.6	18
61	Understanding the metabolism of the anticancer drug Triapine: electrochemical oxidation, microsomal incubation and in vivo analysis using LC-HRMS. Analyst, The, 2017, 142, 3165-3176.	3.5	18
62	The Natural Fungal Metabolite Beauvericin Exerts Anticancer Activity In Vivo: A Pre-Clinical Pilot Study. Toxins, 2017, 9, 258.	3.4	22
63	Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer. Journal of Experimental and Clinical Cancer Research, 2017, 36, 122.	8.6	33
64	FGF5 is expressed in melanoma and enhances malignancyin vitroandin vivo. Oncotarget, 2017, 8, 87750-87762.	1.8	25
65	Promoter methylation patterns of ABCB1, ABCC1 and ABCG2 in human cancer cell lines, multidrug-resistant cell models and tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients. Oncotarget, 2016, 7, 73347-73369.	1.8	31
66	Targeting a Targeted Drug: An Approach Toward Hypoxia‐Activatable Tyrosine Kinase Inhibitor Prodrugs. ChemMedChem, 2016, 11, 2410-2421.	3.2	18
67	Macromolecular Pt(IV) Prodrugs from Poly(organo)phosphazenes. Macromolecular Bioscience, 2016, 16, 1239-1249.	4.1	27
68	Impact of <scp>CYP24A1</scp> overexpression on growth of colorectal tumour xenografts in mice fed with vitamin <scp>D</scp> and soy. International Journal of Cancer, 2016, 138, 440-450.	5.1	29
69	Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro. Molecular Cancer Therapeutics, 2016, 15, 2357-2369.	4.1	17
70	Nanoformulations of anticancer thiosemicarbazones to reduce methemoglobin formation and improve anticancer activity. RSC Advances, 2016, 6, 55848-55859.	3.6	11
71	Impact of Stepwise NH₂-Methylation of Triapine on the Physicochemical Properties, Anticancer Activity, and Resistance Circumvention. Journal of Medicinal Chemistry, 2016, 59, 6739-6752.	6.4	42
72	Behavior of platinum(<scp>iv</scp>) complexes in models of tumor hypoxia: cytotoxicity, compound distribution and accumulation. Metallomics, 2016, 8, 422-433.	2.4	39

#	Article	IF	Citations
73	Multi-scale imaging of anticancer platinum(<scp>iv</scp>) compounds in murine tumor and kidney. Chemical Science, 2016, 7, 3052-3061.	7.4	36
74	Mouse tissue distribution and persistence of the food-born fusariotoxins Enniatin B and Beauvericin. Toxicology Letters, 2016, 247, 35-44.	0.8	51
75	Differences in protein binding and excretion of Triapine and its Fe(III) complex. Journal of Inorganic Biochemistry, 2016, 160, 61-69.	3.5	20
76	Effect of 1,25-dihydroxyvitamin D3 on the Wnt pathway in non-malignant colonic cells. Journal of Steroid Biochemistry and Molecular Biology, 2016, 155, 224-230.	2.5	29
77	Active vitamin D potentiates the anti-neoplastic effects of calcium in the colon: A cross talk through the calcium-sensing receptor. Journal of Steroid Biochemistry and Molecular Biology, 2016, 155, 231-238.	2.5	35
78	Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression. Oncotarget, 2016, 7, 50161-50179.	1.8	19
79	Loss of phosphodiesterase 4D mediates acquired triapine resistance via Epac-Rap1-Integrin signaling. Oncotarget, 2016, 7, 84556-84574.	1.8	15
80	Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells. Oncotarget, 2016, 7, 27379-27393.	1.8	8
81	Fibroblast growth factor receptor 3 isoforms: Novel therapeutic targets for hepatocellular carcinoma?. Hepatology, 2015, 62, 1767-1778.	7.3	33
82	Comparative in vitro and in vivo pharmacological investigation of platinum(IV) complexes as novel anticancer drug candidates for oral application. Journal of Biological Inorganic Chemistry, 2015, 20, 89-99.	2.6	47
83	Application of C₆₀ Fullerene-Doxorubicin Complex for Tumor Cell Treatment <I>In</I> <I>Vitro</I> and <I>In</I> <I>Vivo</I>. Journal of Biomedical Nanotechnology, 2015, 11, 1139-1152.	1.1	83
84	The naturally born fusariotoxin enniatin B and sorafenib exert synergistic activity against cervical cancer in vitro and in vivo. Biochemical Pharmacology, 2015, 93, 318-331.	4.4	28
85	EVI1 promotes tumor growth via transcriptional repression of MS4A3. Journal of Hematology and Oncology, 2015, 8, 28.	17.0	25
86	Triapine-mediated ABCB1 induction via PKC induces widespread therapy unresponsiveness but is not underlying acquired triapine resistance. Cancer Letters, 2015, 361, 112-120.	7.2	24
87	Tumor microenvironment in focus: LA-ICP-MS bioimaging of a preclinical tumor model upon treatment with platinum(iv)-based anticancer agents. Metallomics, 2015, 7, 1256-1264.	2.4	42
88	Structure-Related Mode-of-Action Differences of Anticancer Organoruthenium Complexes with Î²-Diketonates. Journal of Medicinal Chemistry, 2015, 58, 3984-3996.	6.4	74
89	Vanadium(IV/V) complexes of Triapine and related thiosemicarbazones: Synthesis, solution equilibrium and bioactivity. Journal of Inorganic Biochemistry, 2015, 152, 62-73.	3.5	20
90	Metal Drugs. , 2015, , 2782-2785.		0

#	Article	IF	Citations
91	Metal Drugs. , 2015, , 1-4.		0
92	Abstract 4397: Preclinical development of a novel hypoxia-activated EGFR inhibitor using a cobalt(III)-based prodrug design. , 2015, , .		0
93	Abstract 1671: Fibroblast growth factor receptor 3 enhances progression of hepatocellular carcinoma. , 2015, , .		0
94	Abstract 5461: Triapine-mediated ABCB1 induction via PKC induces widespread therapy unresponsiveness but is not underlying acquired triapine resistance. , 2015, , .		0
95	Abstract 2573: Investigation of factors involved in the hypersensitivity to KP1339-treatment. , 2015, , .		0
96	Calpain-Mediated Integrin Deregulation as a Novel Mode of Action for the Anticancer Gallium Compound KP46. Molecular Cancer Therapeutics, 2014, 13, 2436-2449.	4.1	25
97	Specific antioxidant compounds differentially modulate cytotoxic activity of doxorubicin and cisplatin: in vitro and in vivo study. Croatian Medical Journal, 2014, 55, 206-217.	0.7	23
98	Enhanced Anticancer Activity and Circumvention of Resistance Mechanisms by Novel Polymeric/Phospholipidic Nanocarriers of Doxorubicin. Journal of Biomedical Nanotechnology, 2014, 10, 1369-1381.	1.1	21
99	Tumorâ€Targeting of EGFR Inhibitors by Hypoxiaâ€Mediated Activation. Angewandte Chemie - International Edition, 2014, 53, 12930-12935.	13.8	55
100	Fibroblast Growth Factor Receptor Inhibition Is Active against Mesothelioma and Synergizes with Radio- and Chemotherapy. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 763-772.	5.6	59
101	Triapine and a More Potent Dimethyl Derivative Induce Endoplasmic Reticulum Stress in Cancer Cells. Molecular Pharmacology, 2014, 85, 451-459.	2.3	35
102	Waterâ€soluble, biocompatible polyphosphazenes with controllable and pHâ€promoted degradation behavior. Journal of Polymer Science Part A, 2014, 52, 287-294.	2.3	65
103	The study of reduced versus oxidized glutathione in cancer cell models employing isotopically labelled standards. Analytical Methods, 2014, 6, 3086-3094.	2.7	9
104	Silencing of protein kinase D2 induces glioma cell senescence via p53-dependent and -independent pathways. Neuro-Oncology, 2014, 16, 933-945.	1.2	25
105	Poly(lactic acid) nanoparticles of the lead anticancer ruthenium compound KP1019 and its surfactant-mediated activation. Dalton Transactions, 2014, 43, 1096-1104.	3.3	35
106	A Novel Class of Bis- and Tris-Chelate Diam(m)inebis(dicarboxylato)platinum(IV) Complexes as Potential Anticancer Prodrugs. Journal of Medicinal Chemistry, 2014, 57, 6751-6764.	6.4	49
107	NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application. Chemical Science, 2014, 5, 2925-2932.	7.4	552
108	Quantitative bioimaging by LA-ICP-MS: a methodological study on the distribution of Pt and Ru in viscera originating from cisplatin- and KP1339-treated mice. Metallomics, 2014, 6, 1616-1625.	2.4	58

#	Article	IF	Citations
109	Tumorspezifische, Hypoxieâ€basierte Aktivierung von EGFRâ€Inhibitoren. Angewandte Chemie, 2014, 126, 13144-13149.	2.0	8
110	Nanoformulation Improves Activity of the (pre)Clinical Anticancer Ruthenium Complex KP1019. Journal of Biomedical Nanotechnology, 2014, 10, 877-884.	1.1	36
111	X-ray Absorption Near Edge Structure Spectroscopy to Resolve the in Vivo Chemistry of the Redox-Active Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019). Journal of Medicinal Chemistry, 2013, 56, 1182-1196.	6.4	49
112	Maleimide-functionalised platinum(iv) complexes as a synthetic platform for targeted drug delivery. Chemical Communications, 2013, 49, 2249.	4.1	84
113	The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo. European Journal of Cancer, 2013, 49, 3366-3375.	2.8	75
114	In vitro studies on cisplatin focusing on kinetic aspects of intracellular chemistry by LC-ICP-MS. Metallomics, 2013, 5, 636.	2.4	33
115	Metalâ€“Arene Complexes with Indolo[3,2-c]-quinolines: Effects of Ruthenium vs Osmium and Modifications of the Lactam Unit on Intermolecular Interactions, Anticancer Activity, Cell Cycle, and Cellular Accumulation. Organometallics, 2013, 32, 903-914.	2.3	57
116	Destruxins: Fungal-derived cyclohexadepsipeptides with multifaceted anticancer and antiangiogenic activities. Biochemical Pharmacology, 2013, 86, 361-377.	4.4	35
117	Synergistic Anticancer Activity of Arsenic Trioxide with Erlotinib Is Based on Inhibition of EGFR-Mediated DNA Double-Strand Break Repair. Molecular Cancer Therapeutics, 2013, 12, 1073-1084.	4.1	46
118	Ophiobolin A, a sesterterpenoid fungal phytotoxin, displays higher in vitro growth-inhibitory effects in mammalian than in plant cells and displays in vivo antitumor activity. International Journal of Oncology, 2013, 43, 575-585.	3.3	33
119	EVI1 Inhibits Apoptosis Induced by Antileukemic Drugs via Upregulation of CDKN1A/p21/WAF in Human Myeloid Cells. PLoS ONE, 2013, 8, e56308.	2.5	20
120	Osmium(IV) complexes with 1H- and 2H-indazoles: Tautomer identity versus spectroscopic properties and antiproliferative activity. Journal of Inorganic Biochemistry, 2012, 113, 47-54.	3.5	38
121	Trivanillic polyphenols with anticancer cytostatic effects through the targeting of multiple kinases and intracellular Ca²⁺ release. Journal of Cellular and Molecular Medicine, 2012, 16, 1421-1434.	3.6	13
122	Unsymmetric Mono- and Dinuclear Platinum(IV) Complexes Featuring an Ethylene Glycol Moiety: Synthesis, Characterization, and Biological Activity. Journal of Medicinal Chemistry, 2012, 55, 11052-11061.	6.4	34
123	Anticancer Activity of Methyl-Substituted Oxaliplatin Analogs. Molecular Pharmacology, 2012, 81, 719-728.	2.3	54
124	Impact of terminal dimethylation on the resistance profile of Î±-N-heterocyclic thiosemicarbazones. Biochemical Pharmacology, 2012, 83, 1623-1633.	4.4	16
125	Mechanisms underlying reductant-induced reactive oxygen species formation by anticancer copper(II) compounds. Journal of Biological Inorganic Chemistry, 2012, 17, 409-423.	2.6	120
126	Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation. Oncotarget, 2012, 3, 399-413.	1.8	55

#	Article	IF	Citations
127	Quantitative determination of intact free cisplatin in cell models by LC-ICP-MS. Journal of Analytical Atomic Spectrometry, 2011, 26, 109-115.	3.0	21
128	Structural Simplification of Bioactive Natural Products with Multicomponent Synthesis. 3. Fused Uracil-Containing Heterocycles as Novel Topoisomerase-Targeting Agents. Journal of Medicinal Chemistry, 2011, 54, 2012-2021.	6.4	73
129	Anticancer Activity of Metal Complexes: Involvement of Redox Processes. Antioxidants and Redox Signaling, 2011, 15, 1085-1127.	5.4	420
130	EGCG-meditated cyto- and genotoxicity in HaCat keratinocytes is impaired by cell-mediated clearance of auto-oxidation-derived H2O2: An algorithm for experimental setting correction. Toxicology Letters, 2011, 205, 173-182.	0.8	8
131	Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019. Journal of Biological Inorganic Chemistry, 2011, 16, 1205-1215.	2.6	23
132	Fibroblast Growth Factor Receptors as Therapeutic Targets in Human Melanoma: Synergism with BRAF Inhibition. Journal of Investigative Dermatology, 2011, 131, 2087-2095.	0.7	70
133	Abstract 3541: Combination of the ruthenium compound KP1339 with the tyrosine kinase inhibitor sorafenib: A promising approach for the treatment of human hepatoma. , 2011, , .		0
134	Abstract 2637: Terminal dimethyl substitution of Triapine leads to activation of CHOP and induction of apoptosis via ER stress in human colon cancer cells. , 2011, , .		0
135	Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339. Journal of Biological Inorganic Chemistry, 2010, 15, 737-748.	2.6	150
136	Organometallic indolo[3,2-c]quinolines versus indolo[3,2-d]benzazepines: synthesis, structural and spectroscopic characterization, and biological efficacy. Journal of Biological Inorganic Chemistry, 2010, 15, 903-918.	2.6	51
137	Ribonucleotide Reductase as One Important Target of [Tris(1,10- phenanthroline)lanthanum(III)] Trithiocyanate (KP772). Current Cancer Drug Targets, 2009, 9, 595-607.	1.6	21
138	Interactions between ABCâ€transport proteins and the secondary Fusarium metabolites enniatin and beauvericin. Molecular Nutrition and Food Research, 2009, 53, 904-920.	3.3	55
139	Oxidative stress and DNA interactions are not involved in Enniatinâ€•and Beauvericinâ€mediated apoptosis induction. Molecular Nutrition and Food Research, 2009, 53, 1112-1122.	3.3	61
140	The Na+/K+-ATPase is the Achilles Heel of multi-drug-resistant cancer cells. Cancer Letters, 2009, 282, 30-34.	7.2	39
141	Impact of Metal Coordination on Cytotoxicity of 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone (Triapine) and Novel Insights into Terminal Dimethylation. Journal of Medicinal Chemistry, 2009, 52, 5032-5043.	6.4	143
142	Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. Journal of Analytical Atomic Spectrometry, 2009, 24, 51-61.	3.0	100
143	The gallium complex KP46 exerts strong activity against primary explanted melanoma cells and induces apoptosis in melanoma cell lines. Melanoma Research, 2009, 19, 283-293.	1.2	56
144	Resistance against novel anticancer metal compounds: Differences and similarities. Drug Resistance Updates, 2008, 11, 1-16.	14.4	201

#	Article	IF	Citations
145	Enniatin Exerts p53-Dependent Cytostatic and p53-Independent Cytotoxic Activities against Human Cancer Cells. Chemical Research in Toxicology, 2007, 20, 465-473.	3.3	114
146	Metal-Based Paullones as Putative CDK Inhibitors for Antitumor Chemotherapy. Journal of Medicinal Chemistry, 2007, 50, 6343-6355.	6.4	86
147	Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24). Biochemical Pharmacology, 2007, 73, 1873-1886.	4.4	88
148	Mechanisms underlying the anticancer activities of the angucycline landomycin E. Biochemical Pharmacology, 2007, 74, 1713-1726.	4.4	69
149	Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24). Biochemical Pharmacology, 2006, 71, 426-440.	4.4	124
150	Anticancer effects of zoledronic acid against human osteosarcoma cells. Journal of Orthopaedic Research, 2006, 24, 1145-1152.	2.3	72
151	Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells. Journal of Cancer Research and Clinical Oncology, 2005, 131, 101-110.	2.5	186
152	Intrinsic and Acquired Forms of Resistance against the Anticancer Ruthenium Compound KP1019 [Indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A). Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 281-289.	2.5	80